Earlier studies (19–21) also suggested that low-HER2 expression tumors were more likely to respond to RT, which implied that some HER2+ patients who underwent BCS could only attain limited survival benefits compared with patients with other breast cancer subtypes. This evidence concerns the gene ERBB2 and breast cancer.